Kaplan SA - Search Results

1

Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.

Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A. Kaplan SA, et al. Eur Urol. 2013 Jan;63(1):158-65. doi: 10.1016/j.eururo.2012.07.003. Epub 2012 Jul 17. Eur Urol. 2013. PMID: 22831853 Clinical Trial.

2

PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.

Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE. Kaplan SA, et al. Urology. 2002 Sep;60(3):464-8. doi: 10.1016/s0090-4295(02)01760-0. Urology. 2002. PMID: 12350485 Clinical Trial.

3

A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome.

Kaplan SA, Volpe MA, Te AE. Kaplan SA, et al. J Urol. 2004 Jan;171(1):284-8. doi: 10.1097/01.ju.0000101487.83730.80. J Urol. 2004. PMID: 14665895 Clinical Trial.

4

Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity.

Landis JR, Kaplan S, Swift S, Versi E. Landis JR, et al. J Urol. 2004 Feb;171(2 Pt 1):752-6. doi: 10.1097/01.ju.0000103540.71683.e5. J Urol. 2004. PMID: 14713803 Clinical Trial.

5

Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function.

Kaplan SA. Kaplan SA. Urology. 2004 Mar;63(3):428-34. doi: 10.1016/j.urology.2003.09.063. Urology. 2004. PMID: 15028431 Review. No abstract available.

6

Transurethral microwave thermotherapy for benign prostate hyperplasia: separating truth from marketing hype.

Walmsley K, Kaplan SA. Walmsley K, et al. Among authors: kaplan sa. J Urol. 2004 Oct;172(4 Pt 1):1249-55. doi: 10.1097/01.ju.0000129967.30558.ca. J Urol. 2004. PMID: 15371817 Review.

7

High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates.

Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. Sandhu JS, et al. Among authors: kaplan sa. Urology. 2004 Dec;64(6):1155-9. doi: 10.1016/j.urology.2004.07.018. Urology. 2004. PMID: 15596189 Clinical Trial.

8

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Kaplan SA, Walmsley K, Te AE. Kaplan SA, et al. J Urol. 2005 Dec;174(6):2273-5. discussion 2275-6. doi: 10.1097/01.ju.0000181823.33224.a0. J Urol. 2005. PMID: 16280803

9

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.

Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM Jr; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Kaplan SA, et al. J Urol. 2006 Jan;175(1):217-20; discussion 220-1. doi: 10.1016/S0022-5347(05)00041-8. J Urol. 2006. PMID: 16406915 Clinical Trial.

10

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.

Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Abrams P, et al. J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004. doi: 10.1016/S0022-5347(05)00483-0. J Urol. 2006. PMID: 16469601 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,008 results

Search Page